praziquantel has been researched along with Onchocerciasis in 9 studies
azinox: Russian drug
Onchocerciasis: Infection with nematodes of the genus ONCHOCERCA. Characteristics include the presence of firm subcutaneous nodules filled with adult worms, PRURITUS, and ocular lesions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two-arm comparative study in northern Ghana integrated praziquantel distribution into an existing lymphatic filariasis and onchocerciasis control programme using Community Directed Distributors." | 7.77 | Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. ( Aborigo, R; Adjuik, M; Akweongo, P; Amankwa, J; Anto, F; Anyorigiya, T; Asoala, V; Bimi, L; Hodgson, A; Oduro, A, 2011) |
| "We assessed the impact of three annual vs five semiannual rounds of mass drug administration (MDA) with ivermectin plus albendazole followed by praziquantel for the control or elimination of lymphatic filariasis (LF), onchocerciasis, soil-transmitted helminth (STH) infections and schistosomiasis in Lofa County, Liberia." | 5.51 | Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia. ( Bolay, FK; Curtis, K; Eneanya, OA; Fischer, K; Fischer, PU; Gankpala, L; Goss, CW; Gray, EB; Momolu, AT; Nyan, ES; Weil, GJ, 2022) |
| "Our data suggest that co-administration of ivermectin, albendazole and praziquantel is safe in areas where lymphatic filariasis, soil-transmitted helminthiasis and schistosomiasis are co-endemic and where several rounds of treatment with one or two drugs have been implemented in the past." | 5.13 | Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study. ( Biswas, G; Bradley, MH; Chitsulo, L; Engels, D; Gabrielli, AF; Haji, HJ; Mohammed, KA; Molyneux, DH; Mubila, L; Savioli, L, 2008) |
| " The introduction of oxamniquine and praziquantel constitutes a break through in the treatment of intestinal and urogenital schistosomiasis." | 4.76 | [Present status of the treatment of helminthiasis]. ( Coulaud, JP, 1984) |
| "Two-arm comparative study in northern Ghana integrated praziquantel distribution into an existing lymphatic filariasis and onchocerciasis control programme using Community Directed Distributors." | 3.77 | Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. ( Aborigo, R; Adjuik, M; Akweongo, P; Amankwa, J; Anto, F; Anyorigiya, T; Asoala, V; Bimi, L; Hodgson, A; Oduro, A, 2011) |
| " Lastly, widespread neurocysticercosis may be a concern in mass treatment programs that provide praziquantel (for managing schistosomiasis) or albendazole (for managing intestinal worms or lymphatic filariasis) because these drugs may kill cerebral cysticerci, resulting in severe adverse events." | 3.74 | Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures? ( Eberhard, M; Habumogisha, P; Katabarwa, M; Lakwo, T; Richards, F, 2008) |
| "Onchocerciasis is co-endemic with schistosomiasis and intestinal helminths infections, which are all diseases of the rural and the poorest communities in Africa." | 1.32 | Integrated community-directed treatment for the control of onchocerciasis, schistosomiasis and intestinal helminths infections in Uganda: advantages and disadvantages. ( Kabatereine, N; Ndyomugyenyi, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Eneanya, OA | 1 |
| Gankpala, L | 1 |
| Goss, CW | 1 |
| Momolu, AT | 1 |
| Nyan, ES | 1 |
| Gray, EB | 1 |
| Fischer, K | 1 |
| Curtis, K | 1 |
| Bolay, FK | 1 |
| Weil, GJ | 1 |
| Fischer, PU | 1 |
| Anto, F | 1 |
| Asoala, V | 1 |
| Anyorigiya, T | 1 |
| Oduro, A | 1 |
| Adjuik, M | 1 |
| Akweongo, P | 1 |
| Aborigo, R | 1 |
| Bimi, L | 1 |
| Amankwa, J | 1 |
| Hodgson, A | 1 |
| Hopkins, DR | 1 |
| Eigege, A | 2 |
| Miri, ES | 1 |
| Gontor, I | 1 |
| Ogah, G | 1 |
| Umaru, J | 2 |
| Gwomkudu, CC | 1 |
| Mathai, W | 1 |
| Jinadu, M | 1 |
| Amadiegwu, S | 1 |
| Oyenekan, OK | 1 |
| Korve, K | 1 |
| Richards, FO | 1 |
| Ndyomugyenyi, R | 1 |
| Kabatereine, N | 1 |
| Mohammed, KA | 1 |
| Haji, HJ | 1 |
| Gabrielli, AF | 1 |
| Mubila, L | 1 |
| Biswas, G | 1 |
| Chitsulo, L | 1 |
| Bradley, MH | 1 |
| Engels, D | 1 |
| Savioli, L | 1 |
| Molyneux, DH | 1 |
| Pede, E | 1 |
| Miri, E | 1 |
| Ogbu Pearce, P | 1 |
| Jinadu, MY | 1 |
| Njepuome, AN | 1 |
| Katabarwa, M | 1 |
| Lakwo, T | 1 |
| Habumogisha, P | 1 |
| Richards, F | 1 |
| Eberhard, M | 1 |
| Coulaud, JP | 1 |
| Forsyth, KP | 1 |
| Mitchell, GF | 1 |
| Copeman, DB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Can Anthelminthic Treatment Delay the Progression of HIV? Randomised Open-label Trial Testing Presumptive Anthelminthic Treatment on Progression of HIV in ART-naïve HIV-positive Patients in a Rural African Setting With Presumed High Prevalence of Helminth[NCT00817713] | 295 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Terminated prematurely due to recruitment difficulties. Expansion to more study sites not planned.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for praziquantel and Onchocerciasis
| Article | Year |
|---|---|
[Present status of the treatment of helminthiasis].
Topics: Albendazole; Anthelmintics; Benzimidazoles; Cestode Infections; Echinococcosis; Helminthiasis; Human | 1984 |
2 trials available for praziquantel and Onchocerciasis
| Article | Year |
|---|---|
Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia.
Topics: Albendazole; Animals; Cross-Sectional Studies; Elephantiasis, Filarial; Helminthiasis; Humans; Iverm | 2022 |
Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Child; Child, Preschool; Drug Therapy, Combination; E | 2008 |
6 other studies available for praziquantel and Onchocerciasis
| Article | Year |
|---|---|
Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis.
Topics: Adolescent; Albendazole; Child; Drug Therapy, Combination; Elephantiasis, Filarial; Endemic Diseases | 2011 |
Lymphatic filariasis elimination and schistosomiasis control in combination with onchocerciasis control in Nigeria.
Topics: Anthelmintics; Elephantiasis, Filarial; Health Education; Health Knowledge, Attitudes, Practice; Hum | 2002 |
Integrated community-directed treatment for the control of onchocerciasis, schistosomiasis and intestinal helminths infections in Uganda: advantages and disadvantages.
Topics: Adolescent; Anthelmintics; Child; Child, Preschool; Community Health Services; Decision Making; Feas | 2003 |
Triple drug administration (TDA), with praziquantel, ivermectin and albendazole, for the prevention of three neglected tropical diseases in Nigeria.
Topics: Albendazole; Anthelmintics; Antiparasitic Agents; Cost-Benefit Analysis; Drug Interactions; Drug The | 2008 |
Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures?
Topics: Albendazole; Animals; Anthelmintics; Epilepsy; Humans; Neurocysticercosis; Onchocerca; Onchocerciasi | 2008 |
Onchocerca gibsoni: increase of circulating egg antigen with chemotherapy in bovines.
Topics: Animals; Anthelmintics; Antibodies, Monoclonal; Antigens, Surface; Cattle; Diethylcarbamazine; Femal | 1984 |